KemPharm Inc. (NASDAQ:KMPH) Given $26.67 Consensus Target Price by Analysts
KemPharm Inc. (NASDAQ:KMPH) has been assigned a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Analysts have set a 1-year consensus price target of $26.67 for the company and are anticipating that the company will post ($0.70) earnings per share for the current quarter, according to Zacks. Zacks has also given KemPharm an industry rank of 93 out of 265 based on the ratings given to its competitors.
KMPH has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a research report on Tuesday, August 16th. Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a research report on Wednesday, August 10th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating and set a $11.00 target price on shares of KemPharm in a research report on Tuesday, June 14th.
Shares of KemPharm (NASDAQ:KMPH) opened at 4.39 on Wednesday. The stock has a 50 day moving average of $4.67 and a 200-day moving average of $7.67. KemPharm has a 12-month low of $3.52 and a 12-month high of $21.30. The firm’s market capitalization is $64.30 million.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, equities research analysts predict that KemPharm will post ($1.78) EPS for the current fiscal year.
In other KemPharm news, EVP Daniel L. Cohen purchased 10,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $47,500.00. Following the acquisition, the executive vice president now owns 1,310 shares of the company’s stock, valued at $6,222.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 22.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Parkwood LLC acquired a new position in KemPharm during the second quarter worth about $107,000. William Harris Investors Inc. boosted its position in KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 14,911 shares during the last quarter. Menta Capital LLC boosted its position in KemPharm by 11.3% in the first quarter. Menta Capital LLC now owns 11,410 shares of the specialty pharmaceutical company’s stock worth $165,000 after buying an additional 1,154 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in KemPharm by 4.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 35,485 shares of the specialty pharmaceutical company’s stock worth $515,000 after buying an additional 1,653 shares during the last quarter. Finally, Spark Investment Management LLC boosted its position in KemPharm by 195.1% in the second quarter. Spark Investment Management LLC now owns 141,109 shares of the specialty pharmaceutical company’s stock worth $561,000 after buying an additional 93,284 shares during the last quarter. Hedge funds and other institutional investors own 42.65% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.